Want to see JP:4512 full AI Analyst Report?

Wakamoto Pharmaceutical Co., Ltd. (4512) Price & Analysis

0 Followers

4512 Stock Chart & Stats

¥286.00

-¥4.00(-1.79%)

At close: Jan 08 4:00 PM EST

¥286.00

-¥4.00(-1.79%)

Day’s Range― - ―

52-Week Range¥240.00 - ¥380.00

Previous CloseN/A

Volume100.70K

Average Volume (3M)51.74K

Market Cap

¥10.62B

Enterprise Value¥7.82K

Total Cash (Recent Filing)¥3.56B

Total Debt (Recent Filing)¥100.00M

Price to Earnings (P/E)31.0

Beta0.43

Next Earnings

Nov 09, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.14%

Share Statistics

EPS (TTM)-5.12

Shares Outstanding34,838,326

10 Day Avg. Volume66,860

30 Day Avg. Volume51,740

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)1.01

Price to Sales (P/S)1.23

P/FCF Ratio-11.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetVery low leverage reduces financial risk and gives Wakamoto flexibility to fund operations, absorb periods of weaker performance, or pursue investments without heavy dependence on borrowing. This balance-sheet resilience is a durable support for the business over the next several quarters.

Strong Recent Revenue GrowthRecent top-line expansion indicates stronger commercial momentum across the company’s consumer healthcare and pharmaceutical-related activities. If sustained, this growth can improve operating scale, support reinvestment, and strengthen the earnings base despite the company’s historically uneven results.

Stable Gross MarginA consistently high-40% gross margin suggests the product portfolio retains reasonable economics and pricing support before operating costs. This provides a durable foundation for profitability and means future revenue growth could translate into better earnings if execution and expense control improve.

Bears Say

Persistent Negative Cash FlowThree consecutive years of negative operating and free cash flow raise concerns about the conversion of reported earnings into cash and may reflect working-capital or investment demands. Continued cash consumption could reduce financial flexibility over time, even with very low leverage.

Thin And Volatile ProfitabilityThin margins leave limited protection if costs rise or demand weakens, while the history of losses and negative EBIT shows that profitability has not yet been consistently established. This volatility makes medium-term earnings durability more uncertain despite the latest improvement.

Low Return On EquityLow return on equity indicates that Wakamoto is not yet converting its substantial equity base into strong shareholder returns. Unless profitability improves materially, capital may remain underutilized, limiting the long-term compounding potential of the otherwise conservative balance sheet.

4512 FAQ

What was Wakamoto Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Wakamoto Pharmaceutical Co., Ltd. lowest stock price was ¥240.00 and its highest was ¥380.00 in the past 12 months.

What is Wakamoto Pharmaceutical Co., Ltd.’s market cap?

Wakamoto Pharmaceutical Co., Ltd.’s market cap is ¥10.62B.

When is Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date is Nov 09, 2026 which is in 62 days.

How were Wakamoto Pharmaceutical Co., Ltd.’s earnings last quarter?

Wakamoto Pharmaceutical Co., Ltd. released its earnings results on Aug 05, 2026. The company reported ¥0.19 earnings per share for the quarter.

Is Wakamoto Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Wakamoto Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wakamoto Pharmaceutical Co., Ltd. pay dividends?

Wakamoto Pharmaceutical Co., Ltd. pays a Annually dividend of ¥3.5 which represents an annual dividend yield of 1.14%. See more information on Wakamoto Pharmaceutical Co., Ltd. dividends here

What is Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate?

Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wakamoto Pharmaceutical Co., Ltd. have?

Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding.

What happened to Wakamoto Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Wakamoto Pharmaceutical Co., Ltd. reported an EPS of ¥0.19 in its last earnings report. Following the earnings report the stock price went up 2.23%.

Which hedge fund is a major shareholder of Wakamoto Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4512

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wakamoto Pharmaceutical Co., Ltd.

Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely recognized gastrointestinal aid formulated to enhance digestion, regulate intestinal health, and supplement nutrition. Additionally, the company provides AVANTBISE oral tablets, a dietary supplement designed to rebalance the oral microbiome, as well as various medicated toothpastes. Founded in 1929, the enterprise was initially known as Society for Nutrition and Raising Children Co., Ltd. before formally changing its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943.